PD-L1
免疫系统
肿瘤微环境
血液学
癌症
背景(考古学)
癌细胞
转录因子
癌症研究
医学
抄写(语言学)
免疫耐受
限制
内科学
免疫学
免疫疗法
生物
肿瘤科
基因
生物化学
机械工程
古生物学
工程类
语言学
哲学
作者
Ming Yi,Mengke Niu,Linping Xu,Suxia Luo,Kongming Wu
标识
DOI:10.1186/s13045-020-01027-5
摘要
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI